Loading...
Loading...
MolecularMD Corp. and ARIAD Pharmaceuticals
today
announced that MolecularMD has voluntarily withdrawn its Premarketing Approval
(PMA) application to the U.S. Food and Drug Administration (FDA) for its
BCR-ABL T315I Mutation Test. The test detects the BCR-ABL T315I mutation in
chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) patients. The MolecularMD BCR-ABL T315I
Mutation Test was intended as a companion diagnostic for use in conjunction
with ARIAD's investigational BCR-ABL inhibitor, ponatinib, which is currently
under review by the FDA for marketing approval in the U.S.
MolecularMD was recently informed by the FDA's Center for Devices and
Radiological Health that its BCR-ABL T315I Mutation Test is no longer
considered to be a companion diagnostic test for ponatinib. FDA guidance
states that for a clinical laboratory test to be granted a PMA as a companion
diagnostic test, the test must provide information that is essential for the
safe and effective use of a therapeutic product.
“The input provided by the Agency to MolecularMD regarding its T315I mutation
test indicates that the T315I mutation test is no longer required as a
companion diagnostic test to identify patients with the BCR-ABL T315I mutation
who may be treated with ponatinib,” stated Harvey J. Berger, M.D. chairman and
chief executive officer of ARIAD. “We look forward to continuing our
longstanding collaboration with MolecularMD, the world leader in BCR-ABL
testing, in clinical trials of ponatinib in patients with CML.”
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in